Shares of Beta Bionics fell over 35% in January, after the company released preliminary Q4 2025 topline results showing new patient starts of at least 5,581, which trailed Wall Street expectations. In a later filing, Beta Bionics disclosed that it received an FDA warning letter following a June 2025 inspection of its Irvine, California facility, which cited quality system and reporting issues related to the iLet platform. Block & Leviton is investigating.
Contact our attorneys for a no-cost case evaluation.